Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Abbott Laboratories Applies to Register Kaletra Tablet With South Africa

April 5, 2006

Abbott Laboratories announced it has applied to register its heat-resistant Kaletra tablet with South Africa. The tablet can be taken at a lower dose, with or without food, and does not require refrigeration. Critics of the company, including Doctors Without Borders, have accused Abbott of being reluctant to register the new Kaletra formulation in developing countries, where a heat-resistant HIV drug would be ideal. The drug was approved in the United States in October, but is not yet approved in Europe -- an endorsement many African countries require before they will accept shipments. Abbott said it expects Kaletra's approval in Europe by midyear.

Back to other news for April 5, 2006

Adapted from:
Wall Street Journal
04.05.06


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement